News

Bevespi Aerosphere showed a significant improvement in lung function as measured by trough forced expiratory volume in one second (FEV1), compared to its monotherapy components (glycopyrronium 14.4 µg

New investors Cormorant Asset Management, Nextech Invest and others joined founding investor Syncona Ltd, Woodford Investment Management and Arix Bioscience in this Series C round. The funds will

The phase 3 clinical trial dubbed as MINDSET featured 1,315 patients with mild to moderate Alzheimer's disease who were on donepezil therapy over 24 weeks. Intepirdine taken orally

The primary objective for this randomized placebo-controlled, Phase 2 study is to evaluate the efficacy and safety of the immuno-oncology-based combination compared to gemcitabine/ABRAXANE alone. Patients will also

 The complete response letter indicates additional clinical data are needed to further evaluate the safety of sirukumab in the treatment of moderately to severely active RA. "We are

The new company has been launched with a $103m Series A financing. Initially, SpringWorks will work on potential programs for four rare diseases – desmoid tumor, neurofibromatosis, hereditary xerocytosis

The new JV firm will focus on the use of nanolipogel (NLG) technology, which was developed by researchers from Yale University. The technology will enable to encapsulate different

Landos, founded by serial entrepreneur and innovator Dr. Josep Bassaganya-Riera, is advancing a robust pharmaceutical pipeline for autoimmune diseases toward commercialization and will partner operational efforts with Xontogeny,

In conjunction with this achievement, Eleven is ending its large-scale manufacturing activities and redirecting resources toward completing its Phase 3 trial and preparing for discussions with the U.S.